trial · primary record
Pembrolizumab
Solid Tumors
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 3500 |
| Primary completion | 2043-08-04 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT03486873 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:10.697Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03486873
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.